DaVita (DVA)
NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-08
$230.59-1.59%
Close 2026-07-08 · 1-day change
Reading DVA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DVA free→NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-08
Reading DVA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DVA free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on healthcare services. The current thesis state is intact, supported by recent strong financial performance, but there are underlying risks that could impact future results.
The market appears to price DaVita as cheap compared to its peers, with a notable expectations gap. However, the valuation is justified given the current fundamentals and the lack of fragility in the market.
Management has emphasized maintaining operating income guidance, but recent results show a decline. Free cash flow is also below target, indicating a need for improvement, while the near-term risk of missing estimates is low but present.
The thesis hinges on the performance of sector bellwethers like HCA, THC, and EHC. If these companies continue to perform well, it could provide a favorable backdrop for DaVita. Conversely, any negative guidance from these peers could weigh on DaVita's performance.
Over the next 1 to 3 years, DaVita's performance will depend on its ability to navigate sector dynamics and improve its financial metrics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the view that the company's fundamentals are intact, and the maintenance of operating income guidance reinforces confidence in its performance. There are no significant threats noted at this time.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Growth in dialysis treatments is crucial for revenue. A decline could indicate market challenges.
Confirms:Q2 U.S. dialysis treatments show year-over-year growth.
Disproves:Q2 U.S. dialysis treatments decline year over year.
Why it matters: Maintaining operating income above $500 million is key for DaVita's growth outlook. A drop could signal deeper issues.
Confirms:Q2 operating income was more than $500 million.
Disproves:Q2 operating income was less than $500 million.
Why it matters: A drop in revenue growth below median signals potential sector weakness. It could affect DaVita's performance.
Confirms:Health Care sector revenue growth reports show a decline below the median growth rate.
Disproves:Health Care sector revenue growth remains above the median growth rate.
Why it matters: Hitting free cash flow guidance shows good cash management and efficiency.
Confirms:Free cash flow reported between $1,000 million and $1,250 million for Q2 2026.
Disproves:Free cash flow reported below $1,000 million for Q2 2026.
Why it matters: Share buybacks show DaVita values its shareholders. This also shows the company is strong.
Confirms:DaVita announced share buybacks in Q2.
Disproves:No share repurchases announced in Q2.
Why it matters: Free cash flow of at least $1 billion shows DaVita can make cash for growth.
Confirms:Free cash flow reported at or above $1 billion.
Disproves:Free cash flow reported below $1 billion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.